Equity
€239,662 ▼ 12.9%
MEDSYS paid out €123,491 in dividends. That is 140% of the 2025 profit.
MEDSYS
Lifetime
20 annual accounts with figures on one time axis, 32 filings since 1994peak €406,459 (2018)
€170,272▼ 7.0%
lowest -€872,768 (2007)
€87,987▲ 107%
peak €526,696 (2006)
€239,662▼ 12.9%
€164,007▲ 198%
peak 8.6 FTE (2009)
-not published
Board4 names since 2017
2 directors and 1 other
Owners5 names in the annual accounts
100%
Documentsfilings and deeds
29-05-202663 days before the deadline
2025micro format
Result from €42,535 to €87,987Dividend €123,491Equity from €275,166 to €239,662Debts from €55,055 to €164,007Cash from €86,132 to €153,557
Key points
from the 2025 annual accountsTurnover
≈ €430,000 estimated
The micro format states no turnover.
Staff
1 FTE from 8.6 in 2009
Between 2009 and 2025, 88% of the full-time equivalents disappeared.
Liquidity
2.46 was 6.00 in 2024
Short-term debts rose from €55,055 to €164,007.
Filings
32 annual accounts since 1994
Five of the last ten came late. The 2019 accounts came latest: 90 days after the end of the period.
Position in the sector
€87,987
Higher net result than 92% of companies in other manufacturing. Sector median €7,187 · 839 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,386 companies had the same profile as MEDSYS has now. Each dot stands for 79 companies, two years later.
93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,386 companies, not a prediction for MEDSYS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Managing director,
Director, since 04-09-2024
- 100%score equity €233,977 (2025) · 30-09-2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0450817990
2 directors appointed, 2 resignations
Resignations: (managing director) and · Appointments: (director) and (director) · Permanent representative: · General meeting of 04-09-2024 · Gazette deed
Reappointments: (director) and (director)
General meeting of 13-12-2023 · Gazette deed
Reappointments: (managing director) and (director)
General meeting of 26-06-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| MEDSYS Gembloux | €403,669 | €170,272 | 59.4% | - |
| ORTHOPEDIE LANCKMANS Roosdaal | €448,842 | €173,878 | 75.5% | - |
| Orthopedie BRANTS Geel | €376,970 | €146,712 | 75.3% | - |
| Ambachtelijke Orthopedische Schoentechniek Halen | €353,674 | €213,283 | 65.7% | - |
| DENTISCERAM Zaventem | €324,967 | €210,697 | 86.8% | - |
| NOVADENT Boom | €379,500 | €165,044 | 81.8% | - |
| LEXEL Asse | €414,136 | €243,825 | 84.6% | 1.6 |
These companies have the same main activity as MEDSYS: manufacture of medical and dental instruments and supplies (NACE 32500). They are comparable in size and age: total assets between €325,000 and €449,000, founded between 1985 and 1998.
Official details
Source: KBO- Status
- Active since 07-09-1993Normal situation
- Activity
- Manufacture of medical and dental instruments and suppliesNACE 32500
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment unit
- 2.063.512.9695030 Gembloux, since 16-09-1993
- Financial year end
- 31 December
- Peppol
- Reachable since 19-12-2025
Annual accounts 2025
- €403,669▲ 22.2%
- Employeeson 31-12-2025
- 1
- Filing
- Filed on 29-05-2026, 63 days before the end of the filing period
Insights on MEDSYS
MEDSYS files the micro format. That format states no turnover. The gross margin rose from -€115,920 in 2006 to €170,272 in 2025.
holds all the shares. In September 2024, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about MEDSYS
- What is the company number of MEDSYS?
- The company number of MEDSYS is 0450.817.990. The VAT number is the same number with BE in front: BE 0450.817.990.
- Where is MEDSYS based?
- The registered office is at Rue du Gaillard,Sauv. 3, 5030 Gembloux.Company details
- What does MEDSYS do?
- According to the KBO register, the main activity is manufacture of medical and dental instruments and supplies (NACE 32500).
- What is the legal form of MEDSYS?
- MEDSYS is a public limited company (NV).
- When was MEDSYS founded?
- MEDSYS was founded on 07-09-1993.
- Is MEDSYS still active?
- Yes, MEDSYS is an active enterprise in the KBO register.
- How many employees does MEDSYS have?
- MEDSYS had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does MEDSYS fall under?
- In its 2025 annual accounts, MEDSYS states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of MEDSYS?
- The turnover in financial year 2025 is ≈ €430,000. This figure is estimated from the gross margin of €170,272 and 2,201 comparable companies of the same size. It probably lies between €280,000 and €660,000. It is a rough estimate.
- Is MEDSYS profitable?
- In financial year 2025, MEDSYS made a profit of €87,987.
- Where can I find the annual accounts of MEDSYS?
- MEDSYS filed 32 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of MEDSYS due?
- MEDSYS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.